SIRT2 and cancer: In vivo studies demonstrated that SIRT2 inhibitors slowed down the growth of ATRX-deficient glioma xenografts and also induced senescence in these tumors, suggesting a potential therapeutic strategy for treating this aggressive cancer type [72].